用冠状动脉造影探讨无聚合物微孔紫杉醇药物洗脱支架置入后近期和远期随访结果  

Instant and Long Term Impact of YINYI^(TM) Non-Polymeric Paclitaxel Drug Eluting Stent Implantation by Quantitative Coronary Angiography

作　　者：周旭晨[1] 李田昌[2] 梁滨[1] 黄荣翀[1] 张波[1] 尹达[1] 王少鹏[1] 王俊杰[1] 朱皓[1] 张妍[1] 

机构地区：[1]大连医科大学附属第一医院心内科,辽宁省大连市116011 [2]北京同仁医院

出　　处：《中国循环杂志》2010年第5期329-331,共3页Chinese Circulation Journal

摘　　要：目的:前瞻性、非随机探索性研究,用定量冠状动脉(冠脉)造影方法(QCA),评价无聚合物微孔紫杉醇洗脱支架(YINYITMDES)置入冠脉原发(denovo)病变的近期、远期有效性和安全性。方法:2005-03至2005-09月大连医科大学附属第一医院和北京同仁医院的冠心病患者69例,年龄30～70岁,其中男性49例(71.0%),女性20例(29.0%),经冠脉造影(CAG)证实至少一支冠脉狭窄(冠脉原发病变,直径狭窄≥70%),靶病变长度≤26mm,靶血管直径2.5～3.5mm,按照常规方法行冠脉造影并置入YINYITMDES。结果:69例患者共放置79个支架。支架平均直径为(3.21±0.45)mm,置入支架长度平均为(18.29±6.09)mm。69例患者临床平均随访(11±2)个月,随访率100%。其中对45例患者(放置53个支架)在支架置入后9～13个月进行了冠脉造影随访,随访率65.2%。与术前相比,术后即刻最小内腔直径(MLD)明显改善,术前为(0.45±0.27)mm,支架术后为(3.21±0.45)mm,术后9～13个月与术后即刻相比,支架内再狭窄程度为(10.59±12.45)%,最小内腔直径(2.87±0.41)mm,支架内晚期管腔丢失(0.34±0.11)mm;支架内再狭窄率5.7%。结论:无聚合物微孔紫杉醇载药YINYITM对冠脉原发病变有较好的近期和远期治疗作用。Objective ： To investigate the instant and long-term impact of YINYITM non-polymeric Paclitaxel drug eluting stent （ DES ） implantation on coronary artery de novo lesions by quantitative coronary angiography （QCA）. Methods：We summarized 69 patients with coronary artery disease （CAD） from March to September 2005. Coronary angiography confirmed that at lest 1 vessel had de novo lesion with the stenosis≥70% ,the length≤26 mm,and the target vessel diameter within 2. 5-3.5 mm. The patients included 49 male （71%） and 20 female （29%） ,at the age of 30-70 years old. YINYITM non-polymeric Paclitaxel DES were launched on all lesions by percutaneous coronary intervention （PCI） and all patients were followedup for （ 11 ±2） months. Results： There were 79 YINYITM stents launched in all 69 patients. The average diameter of the stems was （3.21 ± 0. 45 ） mm and the length was （ 18. 29 ±6. 09） mm. 45 patients with 53 stents received QCA examination from 9 to 13 months after PCI. The instant minimum lumen diameter （MLD） was improved from （0.45±0. 27）mm pre-PCI to （3.21 ± 0. 45 ）mm post-PCI. During 9-13 months of time, QCA presented that the average MLD was （2. 87±0.41 ） mm,and the late lumen loss was （0. 34 ±0. 11 ） mm. The total in-stent restenosis rate was 5.7%. Conclusion： YINY1TM non-polymeric Paclitaxel DES implantation was beneficial in CAD patients with de novo coronary artery lesions for both instant and long term impact as confirmed by QCA.

关 键 词：无聚合物微孔紫杉醇涂层支架 冠状动脉介入治疗 再狭窄 

分 类 号：R543.3[医药卫生—心血管疾病]